Functional Heartburn

Overview

Functional heartburn is defined as retrosternal burning discomfort or pain that is clinically identical to the heartburn of gastroesophageal reflux disease (GERD), but which occurs in the absence of abnormal esophageal acid exposure on ambulatory reflux monitoring, in the absence of a major esophageal motility disorder on high-resolution manometry, and in the absence of esophageal mucosal pathology — such as erosive esophagitis, Barrett's esophagus, or eosinophilic esophagitis — on endoscopy with biopsies (Fass et al., AGA Clinical Practice Update, 2020). Under the Rome IV framework it is classified not as a reflux disease at all, but as a functional esophageal disorder — a disorder of gut-brain interaction (Gyawali et al., Gastroenterology, 2026).

The reason this page exists, and the reason it matters more than almost any other in reflux care, is a single hard clinical fact: more than two-thirds of patients referred for "refractory heartburn" do not actually have GERD (Domingues et al., Digestive Diseases and Sciences, 2018). When patients with heartburn and a normal endoscopy undergo proper objective testing, functional heartburn and reflux hypersensitivity together account for roughly half of them, and functional heartburn is the most common single diagnosis (Fass, New England Journal of Medicine, 2022). Among patients specifically failing twice-daily proton pump inhibitor (PPI) therapy, 29%–39% have functional heartburn on pH-impedance testing performed off acid suppression (Gyawali and Fass, Gastroenterology, 2018). In one prospective Veterans Affairs study of 366 patients with refractory heartburn, 27% met criteria for functional heartburn on negative esophageal testing (Fass et al., AGA Clinical Practice Update, 2020).

This distinction is not academic. Functional heartburn is important to recognize precisely because, if it is not investigated, it is mistaken for GERD — and treating physicians continue acid-suppressive therapy indefinitely, escalate doses that cannot help, or proceed to invasive antireflux procedures that may cause harm (Fass et al., AGA Clinical Practice Update, 2020). The correct management of functional heartburn is built on the opposite philosophy from the surgical GERD pathway: confirm the diagnosis objectively, stop ineffective acid suppression, and treat the underlying esophageal hypersensitivity (see our PPI-Refractory GERD, Non-Erosive Reflux Disease, and GERD / Acid Reflux pillar pages).

‍

Causes

Functional heartburn is not caused by acid, and this is the central point that separates it from every other condition in the reflux cluster (Fass, New England Journal of Medicine, 2022). The dominant mechanism is esophageal hypersensitivity — a heightened perception of normal or trivial esophageal stimuli — produced by a combination of peripheral and central nervous system changes together with psycho-neuro-immunological interactions (Domingues et al., Digestive Diseases and Sciences, 2018). Several interacting drivers are recognized:

• Altered esophageal pain perception (visceral hypersensitivity). Balloon-distension studies show that functional heartburn patients perceive esophageal — and even rectal — stimuli as painful at lower thresholds than healthy people, pointing to a generalized increase in visceral perception rather than a local acid problem (Fass et al., AGA Clinical Practice Update, 2020).

• A nociceptive, not inflammatory, nerve pattern. Studies of esophageal mucosal afferent nerves show that functional heartburn patients have deep nerve localization similar to healthy volunteers, rather than the superficial nerves seen in non-erosive reflux disease — a structural correlate of a pain-processing disorder (Fass et al., AGA Clinical Practice Update, 2020).

• Central sensitization and brain-gut dysregulation. Heightened esophageal sensation amplifies cognitive-affective processes — esophageal hypervigilance (threat-focused attention to esophageal sensation) and symptom-specific anxiety (worry about the symptom and its consequences) — both of which independently correlate with how severe the heartburn feels (Guadagnoli et al., Clinical Gastroenterology and Hepatology, 2024).

• Overlap with other functional disorders. Functional heartburn frequently coexists with functional dyspepsia, irritable bowel syndrome, and somatization, and there is a high likelihood of concurrent anxiety and other affective disorders — all of which worsen symptom perception and reduce treatment response (Fass et al., AGA Clinical Practice Update, 2020).

‍

Risk Factors

Because functional heartburn is a disorder of gut-brain interaction rather than a reflux disease, its risk factors differ from those on the rest of the reflux cluster:

• Coexisting functional gastrointestinal disorders — particularly functional dyspepsia and irritable bowel syndrome (Fass et al., AGA Clinical Practice Update, 2020).

• Anxiety, depression, and other affective disorders, and a tendency toward somatization (Fass et al., AGA Clinical Practice Update, 2020).

• Esophageal hypervigilance and symptom-specific anxiety, which amplify symptom reporting (Guadagnoli et al., Clinical Gastroenterology and Hepatology, 2024).

• A history of "refractory" heartburn — paradoxically, failure of an adequate PPI trial is itself the strongest clinical clue that heartburn may be functional rather than reflux-driven (Fass, New England Journal of Medicine, 2022).

Notably, there is no difference in heartburn severity between functional heartburn and true GERD, so symptom intensity alone cannot identify who is at risk — only objective testing can (Fass, New England Journal of Medicine, 2022)

‍

How Functional Dyspepsia Affects the Body

In functional heartburn, the esophageal lining is structurally normal and the amount of acid reaching the esophagus is within physiological limits — the problem lies in how esophageal sensation is generated, transmitted, and interpreted (Fass et al., AGA Clinical Practice Update, 2020). Normal or near-normal esophageal events that most people never notice are perceived as burning pain because of a lowered perception threshold at the esophageal nerve level, combined with amplified processing in the central nervous system (Domingues et al., Digestive Diseases and Sciences, 2018). Layered onto this is a learned, self-reinforcing loop: hypervigilant attention to the chest and anxiety about the symptom further magnify the perceived intensity, which drives more attention and more distress (Guadagnoli et al., Clinical Gastroenterology and Hepatology, 2024). Because acid is not the trigger, acid-perfusion studies show functional heartburn patients respond differently from non-erosive reflux disease patients, and acid suppression predictably fails (Fass et al., AGA Clinical Practice Update, 2020). Understanding this mechanism is what makes the difference between effective care and years of futile, escalating treatment.

‍

Complications

The complications of functional heartburn are not the mucosal or anatomic complications of GERD (there is no risk of erosive esophagitis, stricture, or Barrett's esophagus from functional heartburn itself). Instead, the harms are twofold:

• Impaired quality of life and psychological burden. Persistent, treatment-resistant heartburn meaningfully reduces health-related quality of life and is tightly linked to esophageal hypervigilance and symptom-specific anxiety (Guadagnoli et al., Clinical Gastroenterology and Hepatology, 2024).

• Iatrogenic harm from misdiagnosis. This is the complication unique to functional heartburn and the reason the diagnosis must be made correctly. Patients are exposed to indefinite, unnecessary acid suppression, repeated invasive testing, and — most seriously — antireflux surgery or endoscopic antireflux procedures that cannot help and may worsen symptoms. Normal preoperative esophageal acid exposure is a documented risk factor for poor outcomes after fundoplication, including new or worsened dysphagia (Fass et al., AGA Clinical Practice Update, 2020).

‍

Symptoms and Signs

The symptom of functional heartburn is, by definition, indistinguishable from the heartburn of GERD at the bedside (Fass, New England Journal of Medicine, 2022):

• Burning retrosternal discomfort or pain — the dominant and defining symptom.

• Bothersome symptoms occurring at least twice weekly, present for the previous three months, with onset at least six months before diagnosis (Gyawali et al., Gastroenterology, 2026).

• Lack of relief, or only partial relief, despite optimally dosed PPI therapy taken correctly before meals — only 20%–30% of patients achieve relief with high-dose PPIs (Gyawali et al., Gastroenterology, 2026).

• Frequent overlap symptoms of functional dyspepsia (early satiety, epigastric burning) and irritable bowel syndrome (Fass et al., AGA Clinical Practice Update, 2020).

Patients commonly mislabel throat symptoms or epigastric burning as "heartburn," so careful history-taking is essential, and any alarm features — dysphagia, odynophagia, weight loss, anorexia, vomiting, or gastrointestinal bleeding — point away from a functional diagnosis and must be investigated (Fass, New England Journal of Medicine, 2022).

‍

Diagnosis

Functional heartburn is a diagnosis of careful exclusion that cannot be made without objective testing — it is defined by what the testing does not show (Gyawali et al., Gastroenterology, 2026). The required stepwise workup is:

• Upper endoscopy (EGD) with biopsies, ideally off PPI therapy. Endoscopy is first-line but has limited yield on PPI therapy because of high mucosal healing rates; to detect baseline GERD it should ideally be performed after 2–4 weeks off PPIs, and must exclude erosive esophagitis (LA grade B/C/D is now accepted as conclusive GERD), Barrett's esophagus, and eosinophilic esophagitis (see our Erosive Esophagitis and Barrett's Esophagus pages) (Gyawali et al., Gastroenterology, 2026).

• High-resolution esophageal manometry to locate the lower esophageal sphincter and exclude major motor disorders such as achalasia, esophagogastric junction outflow obstruction, distal esophageal spasm, and hypercontractile esophagus per Chicago Classification v4.0 (see our Achalasia page) (Gyawali et al., Gastroenterology, 2026).

• Ambulatory reflux monitoring off therapy — the decisive test. Wireless 96-hour pH monitoring off PPIs is preferred to assess day-to-day acid exposure variability; 24-hour pH-impedance off therapy is an accepted alternative that adds reflux-symptom correlation. GERD is excluded when acid exposure time is <4% on all days with a negative symptom association (Gyawali et al., Gastroenterology, 2026).

• Symptom-reflux association analysis. Functional heartburn is reliably diagnosed in a patient with refractory heartburn, normal endoscopy, normal acid exposure time, and a negative symptom index (SI) and a negative symptom association probability (SAP). If acid exposure is normal but the symptom-reflux association is positive, the diagnosis is instead reflux hypersensitivity — a crucial fork, because that condition can respond to antireflux therapy (see our Reflux Hypersensitivity page) (Fass et al., AGA Clinical Practice Update, 2020).

‍

Differential Diagnosis

The differential is the entire spectrum of heartburn-producing conditions, and distinguishing among them is the whole point of the evaluation (Fass, New England Journal of Medicine, 2022):

• Non-erosive reflux disease (NERD) — identical symptoms but with abnormal acid exposure on monitoring; treat as GERD (see our Non-Erosive Reflux Disease page).

• Reflux hypersensitivity — normal acid exposure but a positive symptom-reflux association; part of the GERD spectrum and may respond to acid suppression or fundoplication (see our Reflux Hypersensitivity page).

• Erosive esophagitis, Barrett's esophagus, and eosinophilic esophagitis — mucosal diseases excluded by endoscopy and biopsy (see our Erosive Esophagitis and Barrett's Esophagus pages).

• Achalasia and other major motility disorders — excluded by manometry (see our Achalasia page).

• PPI-refractory GERD — persistent true reflux despite therapy, distinguished by on-therapy pH-impedance testing (see our PPI-Refractory GERD page).

• Functional chest pain, supragastric belching, rumination syndrome, and functional dyspepsia — other gut-brain disorders that mimic or overlap with functional heartburn (Fass et al., AGA Clinical Practice Update, 2020).

‍

Lifestyle Modifications

Because acid is not the driver, the lifestyle emphasis in functional heartburn shifts away from strict anti-reflux measures and toward addressing the brain-gut axis (Guadagnoli et al., Clinical Gastroenterology and Hepatology, 2024):

• Reassurance and education that no dangerous underlying disease is present — a therapeutic intervention in its own right for a disorder of gut-brain interaction (Gyawali et al., Gastroenterology, 2026).

• Avoiding excessive or disproportionate food avoidance, which is common and counterproductive in these patients and should be actively watched for (Gyawali et al., Gastroenterology, 2026).

• Stress reduction and sleep optimization, given the central role of anxiety and hypervigilance.

• Diaphragmatic breathing and relaxation techniques, which are low-risk and can reduce symptoms (Gyawali et al., Gastroenterology, 2026).

• Discouraging repeated invasive testing once the diagnosis is secure, to break the cycle of health anxiety (Gyawali et al., Gastroenterology, 2026).

Treatment Options

Treatment of functional heartburn is fundamentally different from treatment of GERD, and the first principle is what to stop and what to avoid (Fass et al., AGA Clinical Practice Update, 2020).

What does not work and should be avoided:

• Escalating acid suppression. Acid-suppressive therapy is typically ineffective because acid does not trigger the symptoms; indefinite or escalating PPI therapy should not be continued once the diagnosis is made (Fass et al., AGA Clinical Practice Update, 2020).

• Antireflux surgery (fundoplication) and endoscopic antireflux procedures. Both should be avoided in functional heartburn. Normal preoperative esophageal acid exposure is a risk factor for poor surgical outcomes, and a sham-controlled trial of endoscopic radiofrequency therapy showed no benefit in refractory heartburn patients including those with functional heartburn (Fass et al., AGA Clinical Practice Update, 2020; Gyawali et al., Gastroenterology, 2026). This is the critical boundary that distinguishes functional heartburn from the surgical candidates on our antireflux surgery, Nissen Fundoplication, LINX, and TIF procedure pages.

What does work — treating the hypersensitivity, not the acid:

• Neuromodulators (central first-line therapy). Low-dose tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and gabapentinoids target esophageal hypersensitivity and are the pharmacologic cornerstone, extrapolated from functional chest pain and other gut-brain disorders (Gyawali et al., Gastroenterology, 2026; Domingues et al., Digestive Diseases and Sciences, 2018).

• Brain-gut behavioral therapies. Gut-directed cognitive behavioral therapy and gut-directed hypnotherapy are the best-researched and are effective at reducing symptoms, visceral anxiety, and improving quality of life, particularly where hypervigilance, symptom-specific anxiety, or maladaptive beliefs are present; biofeedback and diaphragmatic breathing are safe adjuncts and can also aid PPI withdrawal (Guadagnoli et al., Clinical Gastroenterology and Hepatology, 2024; Gyawali et al., Gastroenterology, 2026).

• Complementary approaches such as acupuncture and hypnosis may help selected patients, though the supporting evidence is limited (Domingues et al., Digestive Diseases and Sciences, 2018).

‍

When to See a Doctor

Evaluation is warranted for burning chest discomfort that occurs at least twice weekly and persists despite over-the-counter or prescribed acid-blocking medication, especially when symptoms have been present for months (Gyawali et al., Gastroenterology, 2026). Urgent evaluation is needed for any alarm feature — difficulty or painful swallowing, unintentional weight loss, vomiting, anemia, or gastrointestinal bleeding — none of which are features of functional heartburn and all of which require prompt endoscopy to exclude structural or mucosal disease before symptoms are attributed to a functional cause (Fass, New England Journal of Medicine, 2022).

‍

When to Seek Treatment

The single most important time to seek specialized evaluation is when heartburn has not responded to an adequate, correctly dosed PPI trial — because PPI non-response is the central clue that the problem may not be reflux at all (Gyawali et al., Gastroenterology, 2026). Rather than escalating acid suppression or proceeding toward surgery, these patients should be referred for a complete objective workup — endoscopy off PPI, manometry, and ambulatory reflux monitoring — to distinguish functional heartburn from NERD, reflux hypersensitivity, and true PPI-refractory GERD (see our PPI-Refractory GERD page). This phenotyping is precisely what protects a patient from an unnecessary operation, and it should be completed before any antireflux procedure is ever discussed (Fass et al., AGA Clinical Practice Update, 2020).

‍

Long-Term Outlook

Most patients with functional heartburn can achieve meaningful, durable symptom control once care is matched to the true mechanism — a hypersensitive, hypervigilant esophagus rather than an acid problem (Gyawali et al., Gastroenterology, 2026). The long-term plan centers on a sustained neuromodulator and/or behavioral-therapy strategy, deliberate de-escalation of unnecessary acid suppression, avoidance of repeated invasive testing, and treatment of overlapping gut-brain and affective disorders (Guadagnoli et al., Clinical Gastroenterology and Hepatology, 2024). Critically, the long-term outlook is harmed, not helped, by pursuing antireflux surgery in these patients — which is why an experienced foregut program's most valuable contribution here is accurate phenotyping and the discipline to not operate when the objective testing says the problem is not reflux (see our GERD / Acid Reflux pillar).

‍

Prognosis

Functional heartburn is a benign condition in the sense that it carries no risk of the mucosal or anatomic complications of GERD — there is no progression to erosive esophagitis, stricture, or Barrett's esophagus from functional heartburn itself (Fass et al., AGA Clinical Practice Update, 2020). However, as a disorder of gut-brain interaction it tends to be chronic and can be genuinely difficult to treat, with a significant impact on quality of life (Guadagnoli et al., Clinical Gastroenterology and Hepatology, 2024). The prognosis is best when the diagnosis is made confidently and early, ineffective therapies are discontinued, and treatment is redirected toward neuromodulators and brain-gut behavioral therapy; coexisting anxiety, functional dyspepsia, and irritable bowel syndrome worsen the outlook and should be addressed concurrently (Fass et al., AGA Clinical Practice Update, 2020).

‍

Why Choose Dr. de la Cruz-Muñoz

The most important decision a foregut surgeon makes is not how to operate — it is knowing when not to. Functional heartburn is the clearest example: more than two-thirds of patients labeled with "refractory reflux" do not have GERD at all, and operating on them is both futile and potentially harmful. Dr. Nestor de la Cruz-Muñoz, MD, FACS, DABOM, is a board-certified minimally invasive foregut and bariatric surgeon in Miami whose practice is built on rigorous, objective phenotyping of every refractory-heartburn patient before any procedure is considered — endoscopy performed off acid suppression, high-resolution manometry, and ambulatory pH or pH-impedance monitoring — specifically to distinguish functional heartburn and reflux hypersensitivity from true surgical GERD. Patients with functional heartburn are protected from unnecessary fundoplication and endoscopic antireflux procedures and are instead directed to the neuromodulatory and brain-gut behavioral therapies that actually work, in coordination with gastroenterology and gut-brain behavioral specialists. That discernment — reserving antireflux surgery for the patients whose objective testing proves they will benefit — is what makes referring physicians and informed patients trust this practice with the full spectrum of reflux care.

‍